PRESS RELEASES

Date	Title
Nov 30, 2021	Ardelyx Launching IBSRELA® Second Quarter of 2022
Nov 12, 2021	Ardelyx Reports Third Quarter 2021 Financial Results
Nov 11, 2021	Ardelyx to Present at the Jefferies London Healthcare Conference
Nov 5, 2021	Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN's Kidney Week 2021
Nov 4, 2021	Ardelyx to Pursue Formal Dispute Resolution for Tenapanor
Oct 29, 2021	Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021
Oct 13, 2021	Ardelyx Provides Corporate Update Following Type A Meeting with FDA
Sep 3, 2021	Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial
Aug 13, 2021	Ardelyx Reports Second Quarter 2021 Financial Results
Jul 29, 2021	Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com